1
|
Marra G, Laguna MP, Walz J, Pavlovich CP, Bianco F, Gregg J, Lebastchi AH, Lepor H, Macek P, Rais-Bahrami S, Robertson C, Rukstalis D, Salomon G, Ukimura O, Abreu AL, Barbe Y, Cathelineau X, Gandaglia G, George AK, Rivas JG, T Gupta R, Lawrentschuk N, Kasivisvanathan V, Lomas D, Malavaud B, Margolis D, Matsuoka Y, Mehralivand S, Moschini M, Oderda M, Orabi H, Rastinehad AR, Remzi M, Schulman A, Shin T, Shiraishi T, Sidana A, Shoji S, Stabile A, Valerio M, Tammisetti VS, Tan WP, Van Den Bos W, Villers A, Willemse PP, de la Rosette J, Polascik T, Sanchez-Salas R. Molecular biomarkers in the context of focal therapy for prostate cancer: recommendations of a Delphi Consensus from the Focal Therapy Society. Minerva Urol Nefrol 2021. [PMID: 33439577 DOI: 10.23736/s0393-2249.20.04160-0] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
BACKGROUND Focal Therapy (FT) for Prostate Cancer (PCa) is promising. However, long-term oncological results are awaited and there is no consensus on follow-up strategies. Molecular biomarkers (MB) may be useful in selecting, treating and following up men undergoing FT, though there is limited evidence in this field to guide practice. We aimed to conduct a consensus meeting, endorsed by the Focal Therapy Society, amongst a large group of experts, to understand the potential utility of MB in FT for localised PCa. MATERIALS AND METHODS A 38-item questionnaire was built following a literature search. The authors then performed three rounds of a Delphi Consensus using DelphiManager, using the GRADE grid scoring system, followed by a face-to-face expert meeting. Three areas of interest were identified and covered concerning MB for FT, i) the current/present role; ii) the potential/future role; iii) the recommended features for future studies. Consensus was defined using a 70% agreement threshold. RESULTS Of 95 invited experts, 42 (44.2%) completed the three Delphi rounds. Twenty-four items reached a consensus and they were then approved at the meeting involving (n=15) experts. Fourteen items reached a consensus on uncertainty, or they did not reach a consensus. They were re-discussed, resulting in a consensus (n=3), a consensus on a partial agreement (n=1), and a consensus on uncertainty (n=10). A final list of statements were derived from the approved and discussed items, with the addition of three generated statements, to provide guidance regarding MB in the context of FT for localised PCa. Research efforts in this field should be considered a priority. CONCLUSIONS The present study detailed an initial consensus on the use of MB in FT for PCa. This is until evidence becomes available on the subject.
Collapse
Affiliation(s)
- Giancarlo Marra
- Department of Urology, Institut Mutualiste Montsouris, Paris, France.,Department of Urology, Città della Salute e della Scienza, University of Turin, Turin, Italy
| | - Maria Pilar Laguna
- Department of Urology, Institut Universitaire du Cancer Toulouse Oncopole, Toulouse, France
| | - Jochen Walz
- Department of Urology, Institut Paoli-Calmettes, Marseille, France
| | | | - Fernando Bianco
- Department of Urology, NYU Langone Medical Center, New York, NY, USA
| | | | - Amir H Lebastchi
- Department of Urology, Wake Forest Baptist Medical Center, Winston-Salem, NC, USA
| | - Herbert Lepor
- Martini Clinic, Prostate Cancer Center, Hamburg, Germany
| | - Petr Macek
- Department of Urology, Institut Mutualiste Montsouris, Paris, France
| | - Soroush Rais-Bahrami
- Department of Urology, Oita University Faculty of Medicine, Yufu-shi Oita, Japan
| | | | - Daniel Rukstalis
- Department of Urologic Surgery, Vanderbilt University Medical Center, Nashville, TN, USA
| | | | - Osamu Ukimura
- Department of Urology, Erasmus Medical Center, Rotterdam, The Netherlands
| | - Andre L Abreu
- Department of Urology, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
| | - Yann Barbe
- Department of Urology, Institut Mutualiste Montsouris, Paris, France
| | | | - Giorgio Gandaglia
- Department of Urology, Lucerne Kanton Hospital, Lucerne, Switzerland
| | - Arvin K George
- Johns Hopkins University School of Medicine, Baltimore, MD, USA
| | - Juan Gomez Rivas
- Department of Urology, Maimonides Medical Center, Brooklyn, NY, USA
| | - Rajan T Gupta
- Urology at Tokyo Medical and Dental University, Tokyo, Japan -
| | - Nathan Lawrentschuk
- Department of Urology, Keck School of Medicine and University of South California, CA, USA
| | - Veeru Kasivisvanathan
- Department of Radiology and Radiological Sciences, Vanderbilt University Medical Center, Nashville, TN, USA
| | - Derek Lomas
- Urologic Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
| | - Bernard Malavaud
- Department of Urology, University of Alabama at Birmingham, Birmingham, AL, USA
| | - Daniel Margolis
- Division of Urology, University of Cincinnati College of Medicine, Cincinnati, OH, USA
| | - Yoh Matsuoka
- Department of Urology, Tokai University Hachioji Hospital, Hachioji, Tokyo, Japan
| | | | - Marco Moschini
- Department of Urology, Lucerne Kanton Hospital, Lucerne, Switzerland.,Department of Urology, Duke University, Durham, NC, USA
| | - Marco Oderda
- Department of Urology, Città della Salute e della Scienza, University of Turin, Turin, Italy
| | - Hazem Orabi
- Department of Urology, CHU de Lille, Lille, France
| | | | - Mesut Remzi
- Department of Urology, Kyoto Prefectural University of Medicine, Kyoto, Japan
| | - Ariel Schulman
- Department of Urology, Medipol Mega University Hospital, Istanbul, Turkey
| | - Toshitaka Shin
- Urological Research Network, Nova University, Miami, FL, USA
| | - Takumi Shiraishi
- Department of Urology, Erasmus Medical Center, Rotterdam, The Netherlands
| | | | - Sunao Shoji
- Department of Urology, Peter MacCallum Cancer Center, Melbourne, VIC, Australia
| | - Armando Stabile
- Department of Urology, Lucerne Kanton Hospital, Lucerne, Switzerland
| | | | - Varaha S Tammisetti
- Department of Radiology, Weill Cornell Imaging, Cornell University, New York, NY, USA
| | - Wei Phin Tan
- Department of Urology, CHU de Lille, Lille, France
| | | | | | | | - Jean de la Rosette
- Department of Urology, Institut Universitaire du Cancer Toulouse Oncopole, Toulouse, France
| | | | | | | |
Collapse
|